Kristian Wachtell
Position: Head of section, MD, PhD
Phone: +47 48 15 06 59 / +45 51 94 60 64
Email:
 

Author network for Kristian Wachtell by COREMINE medical


Publications 2017

Cwikiel J, Seljeflot I, Berge E, Arnesen H, Wachtell K, Ulsaker H, Flaa A (2017)
Pro-coagulant activity during exercise testing in patients with coronary artery disease
Thromb J, 15, 3
PubMed 28115916

Publications 2016

Blyme A, Asferg C, Nielsen OW, Boman K, Gohlke-Bärwolf C, Wachtell K, Olsen MH (2016)
Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis
Scand Cardiovasc J, 50 (3), 138-45
PubMed 26911132

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Gohlke-Bärwolf C, Kesäniemi YA, Jeppesen JL, Wachtell K (2016)
SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis
Can J Cardiol, 32 (12), 1462-1469
PubMed 27499378

Kjeldsen SE, Aksnes TA, Wachtell K, Okin PM (2016)
Arterial Stiffness Predicts Incident Atrial Fibrillation in the Framingham Heart Study: A Mechanistic Contribution in People With High Blood Pressure or History of Hypertension
Hypertension, 68 (3), 555-7
PubMed 27456524

Mancusi C, Gerdts E, de Simone G, Midtbø H, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB (2016)
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study
Blood Press, 26 (3), 150-155
PubMed 27710139

Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K (2016)
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)
Circulation, 134 (6), 455-68
PubMed 27486164

Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo AP, Hering D, López-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G, Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG (2016)
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
Lancet, 388 (10060), 2665-2712
PubMed 27671667

Wachtell K, Lagerqvist B, Olivecrona GK, James SK, Fröbert O (2016)
Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial
Curr Cardiol Rep, 18 (1), 11
PubMed 26758999

Wachtell K, Okin PM (2016)
An age-old test in old age: ECG left ventricular hypertrophy and cardiovascular outcomes in the elderly
J Hypertens, 34 (11), 2145-6
PubMed 27584974

Waziri H, Jørgensen E, Kelbæk H, Fosbøl EL, Pedersen F, Mogensen UM, Gerds TA, Køber L, Wachtell K (2016)
Acute myocardial infarction and lesion location in the left circumflex artery: importance of coronary artery dominance
EuroIntervention, 12 (4), 441-8
PubMed 26348675

Publications 2015

Bang CN, Greve AM, La Cour M, Boman K, Gohlke-Bärwolf C, Ray S, Pedersen T, Rossebø A, Okin PM, Devereux RB, Wachtell K (2015)
Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
Am J Cardiol, 116 (12), 1840-4
PubMed 26602073

Blyme A, Asferg C, Nielsen OW, Sehestedt T, Kesäniemi YA, Gohlke-Bärwolf C, Boman K, Willenheimer R, Ray S, Nienaber CA, Rossebø A, Wachtell K, Olsen MH (2015)
High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy
Open Heart, 2 (1), e000152
PubMed 25685360

Devereux RB, Bang CN, Roman MJ, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Hille DA, Dahlöf B (2015)
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study
Hypertension, 66 (5), 945-53
PubMed 26418019

Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL (2015)
suPAR: A New Biomarker for Cardiovascular Disease?
Can J Cardiol, 31 (10), 1293-302
PubMed 26118447

Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlöf B, Devereux RB (2015)
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients
Hypertension, 66 (2), 368-73
PubMed 26056336

Okin PM, Hille DA, Wachtell K, Kjeldsen SE, Boman K, Dahlöf B, Devereux RB (2015)
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
J Hypertens, 33 (7), 1480-6
PubMed 25799208

Pareek M, Nielsen ML, Gerke O, Leósdóttir M, Møller JE, Hindersson P, Sehestedt TB, Wachtell K, Nilsson PM, Olsen MH (2015)
Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population
Int J Cardiol, 184, 466-72
PubMed 25756566

Rajamannan NM, Greve AM, Moura LM, Best P, Wachtell K (2015)
SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory
Expert Rev Cardiovasc Ther, 13 (4), 355-67
PubMed 25797901

Seven E, Husemoen LL, Ibsen H, Friedrich N, Nauck M, Wachtell K, Linneberg A, Jeppesen JL (2015)
Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension
PLoS One, 10 (2), e0117864
PubMed 25658326

Seven E, Husemoen LL, Sehested TS, Ibsen H, Wachtell K, Linneberg A, Jeppesen JL (2015)
Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study
PLoS One, 10 (6), e0128987
PubMed 26035431

Vishram JK, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Mancia G, Okin PM, Rothwell PM, Wachtell K, Olsen MH (2015)
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy
J Hypertens, 33 (12), 2422-30
PubMed 26378687

Waziri H, Jørgensen E, Kelbæk H, Stagmo M, Pedersen F, Lagerqvist B, James S, Køber L, Wachtell K (2015)
Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction
Int J Cardiol, 203, 697-701
PubMed 26583845

Publications 2014

Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahlöf B, Køber L, Wachtell K, Devereux RB (2014)
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients
Circ Cardiovasc Imaging, 7 (3), 422-9
PubMed 24723582

Bang CN, Gislason GH, Greve AM, Bang CA, Lilja A, Torp-Pedersen C, Andersen PK, Køber L, Devereux RB, Wachtell K (2014)
New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study
J Am Heart Assoc, 3 (1), e000382
PubMed 24449803

Bang CN, Greve AM, Køber L, Rossebø AB, Ray S, Boman K, Nienaber CA, Devereux RB, Wachtell K (2014)
Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis
Int J Cardiol, 175 (3), 492-8
PubMed 25012498

Bang CN, Okin PM, Køber L, Wachtell K, Gottlieb AB, Devereux RB (2014)
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study
J Hypertens, 32 (3), 667-72
PubMed 24379001

Calais F, Fröbert O, Rosenblad A, Hedberg PO, Wachtell K, Leppert J (2014)
Leisure-time physical inactivity and risk of myocardial infarction and all-cause mortality: a case-control study
Int J Cardiol, 177 (2), 599-600
PubMed 25223818

Greve AM, Bang CN, Berg RM, Egstrup K, Rossebø AB, Boman K, Nienaber CA, Ray S, Gohlke-Baerwolf C, Nielsen OW, Okin PM, Devereux RB, Køber L, Wachtell K (2014)
Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study
Int J Cardiol, 180, 122-8
PubMed 25438232

Greve AM, Dalsgaard M, Bang CN, Egstrup K, Ray S, Boman K, Rossebø AB, Gohlke-Baerwolf C, Devereux RB, Køber L, Wachtell K (2014)
Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
Stroke, 45 (7), 1939-46
PubMed 24903982

Greve AM, Dalsgaard M, Bang CN, Egstrup K, Rossebø AB, Boman K, Cramariuc D, Nienaber CA, Ray S, Gohlke-Baerwolf C, Okin PM, Devereux RB, Køber L, Wachtell K (2014)
Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
Am J Cardiol, 114 (5), 751-6
PubMed 25048345

Jander N, Hochholzer W, Kaufmann BA, Bahlmann E, Gerdts E, Boman K, Chambers JB, Nienaber CA, Ray S, Rossebo A, Pedersen TR, Wachtell K, Gohlke-Bärwolf C, Neumann FJ, Minners J (2014)
Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF
Heart, 100 (24), 1946-53
PubMed 25217488

Kruger R, Rasmussen LM, Argraves WS, Eugen-Olsen J, Nielsen OW, Blyme A, Willenheimer R, Wachtell K, Olsen MH (2014)
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study)
PLoS One, 9 (7), e101522
PubMed 25014213

Mancusi C, Gerdts E, De Simone G, Abdelhai YM, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB (2014)
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study)
Blood Press, 23 (4), 206-12
PubMed 24564262

Minners J, Gohlke-Baerwolf C, Kaufmann BA, Bahlmann E, Gerdts E, Boman K, Chambers JB, Nienaber CA, Willenheimer R, Wachtell K, Holme I, Pedersen TR, Neumann FJ, Jander N (2014)
Adjusting parameters of aortic valve stenosis severity by body size
Heart, 100 (13), 1024-30
PubMed 24780909

Mohr FW, Holzhey DM, Wachtell K, Nienaber CA (2014)
[Indication for TAVI in Germany--the German aortic valve registry]
Dtsch Med Wochenschr, 139 (39), 1954-8
PubMed 25225868

Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB (2014)
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy
Am J Hypertens, 27 (7), 966-72
PubMed 24552888

Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB (2014)
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure
J Hypertens, 32 (12), 2472-8; discussion 2478
PubMed 25340854

Pedersen F, Butrymovich V, Kelbæk H, Wachtell K, Helqvist S, Kastrup J, Holmvang L, Clemmensen P, Engstrøm T, Grande P, Saunamäki K, Jørgensen E (2014)
Short- and long-term cause of death in patients treated with primary PCI for STEMI
J Am Coll Cardiol, 64 (20), 2101-8
PubMed 25457398

Seven E, Husemoen LL, Wachtell K, Ibsen H, Linneberg A, Jeppesen JL (2014)
Overweight, adipocytokines and hypertension: a prospective population-based study
J Hypertens, 32 (7), 1488-94; discussion 1494
PubMed 24805956

Seven E, Husemoen LL, Wachtell K, Ibsen H, Linneberg A, Jeppesen JL (2014)
Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin
J Hypertens, 32 (11), 2231-7; discussion 2237
PubMed 25275249

Thomsen JH, Kjaergaard J, Saust LT, Wachtell K, Hassager C (2014)
[Thrombosis of a mechanical prosthetic mitral valve during dabigatran treatment]
Ugeskr Laeger, 176 (12A)
PubMed 25350892

Wachtell K, Greve AM (2014)
Structural and functional cardiac changes are target organ damage that increases risk of atrial fibrillation
J Am Coll Cardiol, 63 (19), 2014-5
PubMed 24657691

Publications 2013

Bahlmann E, Gerdts E, Cramariuc D, Gohlke-Baerwolf C, Nienaber CA, Wachtell K, Seifert R, Chambers JB, Kuck KH, Ray S (2013)
Prognostic value of energy loss index in asymptomatic aortic stenosis
Circulation, 127 (10), 1149-56
PubMed 23357717

Bang CN, Dalsgaard M, Greve AM, Køber L, Gohlke-Baerwolf C, Ray S, Rossebø AB, Egstrup K, Wachtell K (2013)
Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study
Int J Cardiol, 168 (3), 2322-7
PubMed 23416018

Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Roman MJ, Køber L, Wachtell K, Devereux RB (2013)
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 31 (10), 2060-8
PubMed 23838656

Dalsgaard M, Egstrup K, Wachtell K, Cramariuc D, Kjaergaard J, Gerdts E, Hassager C (2013)
Left atrial volume as predictor of valve replacement and cardiovascular events in patients with asymptomatic mild to moderate aortic stenosis
Echocardiography, 30 (9), 1008-14
PubMed 23551697

De Marco M, Gerdts E, Casalnuovo G, Migliore T, Wachtell K, Boman K, Dahlöf B, Olsen MH, Kizer JR, Devereux RB, de Simone G (2013)
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study
Am J Hypertens, 26 (4), 567-73
PubMed 23391619

Gohlke-Bärwolf C, Minners J, Jander N, Gerdts E, Wachtell K, Ray S, Pedersen TR (2013)
Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study
Curr Probl Cardiol, 38 (9), 365-409
PubMed 23972937

Jander N, Gohlke-Bärwolf C, Bahlmann E, Gerdts E, Boman K, Chambers JB, Egstrup K, Nienaber CA, Pedersen TR, Ray S, Rossebø AB, Willenheimer R, Kienzle RP, Wachtell K, Neumann FJ, Minners J (2013)
Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis
Heart, 100 (1), 28-33
PubMed 23969478

Nielsen JR, Wachtell K, Abdulla J (2013)
The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis
J Atr Fibrillation, 5 (5), 789
PubMed 28496815

Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB (2013)
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy
Circ Arrhythm Electrophysiol, 6 (2), 243-51
PubMed 23403268

Smink PA, Hoekman J, Grobbee DE, Eijkemans MJ, Parving HH, Persson F, Ibsen H, Lindholm L, Wachtell K, de Zeeuw D, Heerspink HJ (2013)
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers
Eur J Prev Cardiol, 21 (4), 434-41
PubMed 23467676

Wachtell K (2013)
When to operate: severe aortic stenosis is still a clinical enigma
Am J Cardiol, 112 (9), 1510-1
PubMed 23910431

Wachtell K, Okin PM (2013)
Regression of target organ damage
J Hypertens, 31 (8), 1535-6
PubMed 23822926

Publications 2012

Bang CN, Gislason GH, Greve AM, Torp-Pedersen C, Køber L, Wachtell K (2012)
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study
Eur J Prev Cardiol, 21 (3), 330-8
PubMed 23012689

Bang CN, Greve AM, Abdulla J, Køber L, Gislason GH, Wachtell K (2012)
The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis
Int J Cardiol, 167 (3), 624-30
PubMed 22999824

Bang CN, Greve AM, Boman K, Egstrup K, Gohlke-Baerwolf C, Køber L, Nienaber CA, Ray S, Rossebø AB, Wachtell K (2012)
Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
Am Heart J, 163 (4), 690-6
PubMed 22520536

Bang CN, Greve AM, Wachtell K, Kober L (2012)
Global systolic load, left ventricular hypertrophy, and atrial fibrillation
Am Heart J, 164 (4), e13
PubMed 23067925

Gerdts E, Okin PM, Boman K, Wachtell K, Nieminen MS, Dahlöf B, Devereux RB (2012)
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy
Am J Hypertens, 25 (6), 678-83
PubMed 22456225

Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Devereux RB, Køber L, Ray S, Willenheimer R, Wachtell K (2012)
Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
J Am Coll Cardiol, 59 (13), 1142-9
PubMed 22440214

Greve AM, Olsen MH, Bella JN, Lønnebakken MT, Gerdts E, Okin PM, Palmieri V, Boman K, Nieminen MS, Omvik P, Dahlöf B, Devereux RB, Wachtell K (2012)
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study
Am J Hypertens, 25 (9), 1017-23
PubMed 22695506

Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Dahlöf B, Kjeldsen SE, Wachtell K (2012)
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study
Hypertension, 60 (2), 347-53
PubMed 22753219

Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K (2012)
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study
Am J Hypertens, 25 (10), 1101-9
PubMed 22717544

Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH (2012)
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
J Hypertens, 30 (6), 1252-9
PubMed 22499288

Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH (2012)
Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?
J Hypertens, 30 (3), 513-21
PubMed 22241138

Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH (2012)
Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts
J Hypertens, 30 (10), 1928-36
PubMed 22871892

Søholm H, Wachtell K, Nielsen SL, Bro-Jeppesen J, Pedersen F, Wanscher M, Boesgaard S, Møller JE, Hassager C, Kjaergaard J (2012)
Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest
Resuscitation, 84 (2), 162-7
PubMed 22796541

Publications 2011

Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlöf B, Wachtell K (2011)
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study
Blood Press, 21 (1), 6-11
PubMed 22070095

Bahlmann E, Nienaber CA, Cramariuc D, Gohlke-Baerwolf C, Ray S, Devereux RB, Wachtell K, Kuck KH, Davidsen E, Gerdts E (2011)
Aortic root geometry in aortic stenosis patients (a SEAS substudy)
Eur J Echocardiogr, 12 (8), 585-90
PubMed 21508001

Gerdts E, de Simone G, Lund BP, Okin PM, Wachtell K, Boman K, Nieminen MS, Dahlöf B, Devereux RB (2011)
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment
Nutr Metab Cardiovasc Dis, 23 (2), 122-9
PubMed 21775111

Greve AM, Boman K, Gohlke-Baerwolf C, Kesäniemi YA, Nienaber C, Ray S, Egstrup K, Rossebø AB, Devereux RB, Køber L, Willenheimer R, Wachtell K (2011)
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
Circulation, 125 (2), 346-53
PubMed 22147903

Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Hammer-Hansen S, Køber L, Willenheimer R, Wachtell K (2011)
Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data)
Am J Cardiol, 108 (4), 541-7
PubMed 21624542

Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Nienaber CA, Ray S, Egstrup K, Pedersen TR, Køber L, Willenheimer R, Wachtell K (2011)
Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
Int J Cardiol, 166 (1), 72-6
PubMed 21996417

Holme I, Pedersen TR, Boman K, Egstrup K, Gerdts E, Kesäniemi YA, Malbecq W, Ray S, Rossebø AB, Wachtell K, Willenheimer R, Gohlke-Bärwolf C (2011)
A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis
Heart, 98 (5), 377-83
PubMed 22155702

Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C (2011)
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction
Circulation, 123 (8), 887-95
PubMed 21321152

Jander N, Minners J, Neumann FJ, Gohlke-Barwolf C, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebo A, Pedersen TR, Skjaerpe T, Willenheimer R, Wachtell K (2011)
Response to Letters Regarding Article, "Outcome of Patients With Low-Gradient "Severe" Aortic Stenosis and Preserved Ejection Fraction"
Circulation, 124 (13), E362-E363

Lønnebakken MT, Gerdts E, Boman K, Wachtell K, Dahlöf B, Devereux RB (2011)
In-treatment stroke volume predicts cardiovascular risk in hypertension
J Hypertens, 29 (8), 1508-14
PubMed 21720264

Olsen MH, Wachtell K, Ibsen H, Lindholm L, Kjeldsen SE, Omvik P, Nieminen MS, Dahlöf B, Okin PM, Devereux RB (2011)
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy
J Hypertens, 29 (5), 997-1004
PubMed 21358415

Wachtell K, Olsen MH (2011)
Impaired left ventricular systolic function in patients with left ventricular hypertrophy
J Hypertens, 29 (11), 2068-9
PubMed 21989381

Publications 2010

Bahlmann E, Cramariuc D, Gerdts E, Gohlke-Baerwolf C, Nienaber CA, Eriksen E, Wachtell K, Chambers J, Kuck KH, Ray S (2010)
Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy
JACC Cardiovasc Imaging, 3 (6), 555-62
PubMed 20541709

Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R (2010)
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study)
Am J Cardiol, 106 (11), 1634-9
PubMed 21094366

Holme I, Boman K, Brudi P, Egstrup K, Gohlke-Baerwolf C, Kesäniemi YA, Malbecq W, Rossebø AB, Wachtell K, Willenheimer R, Pedersen TR (2010)
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial
Am J Cardiol, 105 (12), 1802-8
PubMed 20538134

Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K (2010)
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study
J Hum Hypertens, 25 (3), 178-85
PubMed 20505749

Okin PM, Gerdts E, Wachtell K, Oikarinen L, Nieminen MS, Dahlöf B, Devereux RB (2010)
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation
J Hypertens, 28 (7), 1534-40
PubMed 20589977

Olsen MH, Sehestedt T, Lyngbaek S, Hansen TW, Rasmussen S, Wachtell K, Torp-Pedersen C, Hildebrandt PR, Ibsen H (2010)
Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?
Curr Vasc Pharmacol, 8 (1), 134-9
PubMed 19485906

Rieck AE, Cramariuc D, Staal EM, Rossebø AB, Wachtell K, Gerdts E (2010)
Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy)
J Hypertens, 28 (2), 377-83
PubMed 19844185

Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010)
Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis
J Am Coll Cardiol, 55 (21), 2299-307
PubMed 20488299

Søraas CL, Wachtell K, Okin PM, Dahlöf B, Devereux RB, Tønnessen T, Kjeldsen SE, Olsen MH (2010)
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study
Blood Press, 19 (3), 145-51
PubMed 20429689

Tuseth N, Cramariuc D, Rieck AE, Wachtell K, Gerdts E (2010)
Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy)
Blood Press, 19 (3), 140-4
PubMed 20429691

Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB (2010)
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
Blood Press, 19 (3), 169-75
PubMed 20438307

Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma GP, Rokkedal JE, Devereux RB (2010)
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study
J Hypertens, 28 (7), 1541-6
PubMed 20410835

Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahlöf B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB (2010)
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study)
Am J Cardiol, 106 (7), 999-1005
PubMed 20854964

Wiik BP, Larstorp AC, Høieggen A, Kjeldsen SE, Olsen MH, Ibsen H, Lindholm L, Dahlöf B, Devereux RB, Okin PM, Wachtell K (2010)
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study
Am J Hypertens, 23 (8), 845-51
PubMed 20431530

Publications 2009

Boman K, Gerdts E, Wachtell K, Dahlöf B, Nieminen MS, Olofsson M, Papademetriou V, Devereux RB (2009)
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study
Eur J Cardiovasc Prev Rehabil, 16 (2), 242-8
PubMed 19369828

Chinali M, Aurigemma GP, de Simone G, Mishra RK, Gerdts E, Wachtell K, Boman K, Dahlöf B, Devereux RB (2009)
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy)
Am J Cardiol, 104 (8), 1098-104
PubMed 19801032

Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K, Gerdts E (2009)
Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy
JACC Cardiovasc Imaging, 2 (4), 390-9
PubMed 19580719

de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Kjeldsen SE, Devereux RB (2009)
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study
Nutr Metab Cardiovasc Dis, 19 (9), 634-40
PubMed 19361968

Gerdts E, Franklin S, Rieck A, Papademetriou V, Wachtell K, Nieminen M, Dahlöf B, Devereux RB (2009)
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study)
Blood Press, 18 (4), 180-6
PubMed 19562573

Gerdts E, Okin PM, Omvik P, Wachtell K, Dahlöf B, Hildebrandt P, Nieminen MS, Devereux RB (2009)
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study
Nutr Metab Cardiovasc Dis, 19 (5), 306-12
PubMed 19303268

Olsen LK, Engstrøm T, Wachtell K, Kristensen T, Hassager C, Ihlemann N, Møller JE, Andersen LW, Olsen PS, Søndergaard L (2009)
[Percutaneous aortic valve replacement - initial experience and results]
Ugeskr Laeger, 171 (15), 1289-93
PubMed 19416621

Olsen LK, Engstrøm T, Wachtell K, Kristensen T, Hassager C, Ihlemann N, Møller JE, Andersen LW, Olsen PS, Søndergaard L (2009)
[Transcatheter replacement of the aortic valve--a novel treatment modality for high-risk patients]
Ugeskr Laeger, 171 (15), 1293-7
PubMed 19416622

Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Lyle PA, Nieminen MS, Omvik P, Oparil S, Wedel H (2009)
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 27 (3), 567-74
PubMed 19262226

Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH (2009)
Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?
J Hypertens, 27 (6), 1165-71
PubMed 19387364

Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH (2009)
Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population
J Hypertens, 27 (12), 2351-7
PubMed 19915482

Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt P, Olsen MH (2009)
Risk prediction is improved by adding markers of subclinical organ damage to SCORE
Eur Heart J, 31 (7), 883-91
PubMed 20034972

Wachtell K (2009)
Prevention of congestive heart failure in high risk patients
Eur Heart J, 30 (6), 638-9
PubMed 19240069

Wachtell K (2009)
Atrial fibrillation, maybe it is not so lone?
J Am Coll Cardiol, 53 (1), 30-1
PubMed 19118721

Wachtell K, Andersen NH, Svendsen TL (2009)
[Hypertension and the heart]
Ugeskr Laeger, 171 (25), 2113-6
PubMed 19671394

Publications 2008

Chinali M, de Simone G, Wachtell K, Gerdts E, Gardin JM, Boman K, Nieminen MS, Papademetriou V, Dahlöf B, Devereux RB (2008)
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study
J Hypertens, 26 (7), 1472-6
PubMed 18551025

Cicala S, de Simone G, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB (2008)
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study
J Hypertens, 26 (4), 806-12
PubMed 18327092

Dalsgaard M, Egstrup K, Wachtell K, Gerdts E, Cramariuc D, Kjaergaard J, Hassager C (2008)
Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study)
Am J Cardiol, 101 (7), 1030-4
PubMed 18359326

Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB (2008)
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)
Eur J Echocardiogr, 9 (6), 809-15
PubMed 18490279

Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, Devereux RB (2008)
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study
Hypertension, 51 (4), 1109-14
PubMed 18259011

Greve AM, Wachtell K (2008)
Does lowering cholesterol have an impact on the progression of aortic stenosis?
Ther Adv Cardiovasc Dis, 2 (4), 277-86
PubMed 19124427

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE (2008)
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes
J Nephrol, 21 (4), 566-9
PubMed 18651547

Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB (2008)
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study
J Hypertens, 26 (6), 1244-9
PubMed 18475164

Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, Dahlöf B, LIFE Study Investigators (2008)
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study
Am J Hypertens, 21 (3), 273-9
PubMed 18219298

Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB (2008)
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study
Circ Arrhythm Electrophysiol, 1 (5), 337-43
PubMed 19808428

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2008)
New risk markers may change the HeartScore risk classification significantly in one-fifth of the population
J Hum Hypertens, 23 (2), 105-12
PubMed 18784734

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2008)
Impact of the metabolic syndrome on the predictive values of new risk markers in the general population
J Hum Hypertens, 22 (9), 634-40
PubMed 18528412

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2008)
Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex
J Hypertens, 26 (1), 26-34
PubMed 18090537

Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H (2008)
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study
Am Heart J, 157 (1), 177-84
PubMed 19081416

Palmieri V, Bella JN, Gerdts E, Wachtell K, Papademetriou V, Nieminen MS, Dahlöf B, Devereux RB (2008)
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study
Am J Hypertens, 21 (6), 701-7
PubMed 18437127

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
N Engl J Med, 359 (13), 1343-56
PubMed 18765433

Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E (2008)
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
Ther Adv Cardiovasc Dis, 2 (6), 507-13
PubMed 19124445

Wachtell K, Olsen MH (2008)
Is it time to change the definition of normal urinary albumin excretion?
Nat Clin Pract Nephrol, 4 (12), 650-1
PubMed 18852732

Publications 2007

Bang LE, Wiinberg N, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Ibsen H (2007)
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy
Blood Press, 16 (6), 392-7
PubMed 18058457

Cicala S, Devereux RB, de Simone G, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Dahlöf B, Okin PM (2007)
Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study
Am J Hypertens, 20 (7), 771-6
PubMed 17586412

Cramariuc D, Rieck AE, Staal EM, Wachtell K, Eriksen E, Rossebø AB, Gerdts E (2007)
Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy)
Am J Cardiol, 101 (4), 510-5
PubMed 18312768

de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB (2007)
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study
J Hum Hypertens, 21 (8), 625-32
PubMed 17476291

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D (2007)
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
J Hypertens, 25 (4), 871-6
PubMed 17351381

Høfsten DE, Wachtell K, Lund B, Mølgaard H, Egstrup K (2007)
Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty
Eur Heart J, 28 (4), 407-14
PubMed 17227787

Idorn L, Høfsten DE, Wachtell K, Mølgaard H, Egstrup K, DANAMI-2 Investigators (2007)
Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy)
Am J Cardiol, 100 (6), 937-43
PubMed 17826373

Lindholm MG, Engstrøm T, Wachtell K, Boesgaard S, Sander K, Hassager C (2007)
[Percutaneous assist device during acute heart failure]
Ugeskr Laeger, 169 (39), 3282-6
PubMed 17953886

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2007)
N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population
Eur Heart J, 28 (11), 1374-81
PubMed 17242007

Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB (2007)
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study
J Hypertens, 25 (5), 1079-85
PubMed 17414673

Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2007)
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study
Am J Cardiol, 99 (7), 970-3
PubMed 17398194

Valeur N, Clemmensen P, Grande P, Wachtell K, Saunamaki K (2007)
Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study
Cardiology, 109 (3), 163-71
PubMed 17726317

Wachtell K, Devereux RB, Lyle AP (2007)
The effect of angiotensin receptor blockers for preventing atrial fibrillation
Curr Hypertens Rep, 9 (4), 278-83
PubMed 17686377

Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K (2007)
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study
Circulation, 116 (7), 700-5
PubMed 17664372

Publications 2006

Christensen MK, Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE, Hildebrandt P, Rokkedal J, Ibsen H (2006)
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy
Blood Press, 15 (4), 198-206
PubMed 17078155

Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Kjeldsen SE, Ibsen H, Wan Y, Julius S (2006)
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy
J Clin Hypertens (Greenwich), 8 (3), 169-73
PubMed 16522993

Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, Dahlöf B, Devereux RB (2006)
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial
Hypertension, 49 (2), 311-6
PubMed 17178978

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA (2006)
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study
Diabetes Care, 29 (3), 595-600
PubMed 16505512

Larroude CE, Jensen BT, Agner E, Toft E, Torp-Pedersen C, Wachtell K, Kanters JK (2006)
Beat-to-beat QT dynamics in paroxysmal atrial fibrillation
Heart Rhythm, 3 (6), 660-4
PubMed 16731466

Narayan P, Papademetriou V, Wachtell K, Gerdts E, Boman K, Nieminen MS, de Simone G, Dahlöf B, Fyhrquist F, Hoieggen A, Devereux RB (2006)
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study
Hypertension, 47 (5), 868-73
PubMed 16567586

Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B (2006)
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
JAMA, 296 (10), 1242-8
PubMed 16968848

Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P (2006)
High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors
J Hypertens, 24 (4), 655-61
PubMed 16531793

Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS (2006)
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study
J Hum Hypertens, 20 (6), 460-4
PubMed 16572193

Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM, LIFE Study Investigators (2006)
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study
J Hypertens, 24 (4), 775-81
PubMed 16531808

Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR (2006)
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
J Hypertens, 24 (8), 1531-9
PubMed 16877955

Palmieri V, Okin PM, Bella JN, Wachtell K, Oikarinen L, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB (2006)
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study
J Hypertens, 24 (10), 2079-84
PubMed 16957569

Wachtell K, Devereux RB, Lyle PA (2006)
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation
Curr Cardiol Rep, 8 (5), 356-64
PubMed 16956451

Publications 2005

Boman K, Olofsson M, Dahlöf B, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Devereux RB (2005)
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study)
Am J Cardiol, 95 (2), 280-3
PubMed 15642571

de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB (2005)
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study
Circulation, 111 (15), 1924-31
PubMed 15837945

Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, Ibsen H, Kjeldsen SE, Dahlöf B (2005)
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy
Hypertension, 46 (3), 492-9
PubMed 16116047

Hildebrandt P, Wachtell K, Dahlöf B, Papademitriou V, Gerdts E, Giles T, Oikarinen L, Tuxen C, Olsen MH, Devereux RB (2005)
Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study
Diabet Med, 22 (8), 1005-11
PubMed 16026365

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y (2005)
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
Hypertension, 45 (2), 198-202
PubMed 15655123

Jensen BT, Abildstrom SZ, Larroude CE, Agner E, Torp-Pedersen C, Nyvad O, Ottesen M, Wachtell K, Kanters JK (2005)
QT dynamics in risk stratification after myocardial infarction
Heart Rhythm, 2 (4), 357-64
PubMed 15851335

Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, Holm S, Hesse B (2005)
Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy
Am J Cardiol, 96 (12), 1692-8
PubMed 16360359

Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE, Hildebrandt P, Dige-Petersen H, Rokkedal J, Ibsen H (2005)
Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy
J Hum Hypertens, 19 (4), 301-7
PubMed 15647776

Olsen MH, Fossum E, Høieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S (2005)
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy
J Hypertens, 23 (4), 891-8
PubMed 15775796

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P (2005)
N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome
Hypertension, 46 (4), 660-6
PubMed 16129819

Olsen MH, Wachtell K, Bella JN, Gerdts E, Palmieri V, Nieminen MS, Smith G, Ibsen H, Devereux RB, LIFE substudy (2005)
Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy)
Am J Cardiol, 95 (1), 132-6
PubMed 15619412

Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB (2005)
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy
Am J Hypertens, 18 (11), 1430-6
PubMed 16280277

Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, Ibsen H (2005)
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy
Blood Press, 14 (3), 177-83
PubMed 16036498

Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt PR (2005)
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy
J Hypertens, 23 (5), 1083-90
PubMed 15834296

Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005)
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol, 45 (5), 705-11
PubMed 15734614

Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005)
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol, 45 (5), 712-9
PubMed 15734615

Publications 2004

Bella JN, Palmieri V, Wachtell K, Liu JE, Gerdts E, Nieminen MS, Koren MJ, Zabalgoitia M, Wright JT, Dahlöf B, Devereux RB (2004)
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study
J Hum Hypertens, 18 (6), 411-6
PubMed 15042116

Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K (2004)
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
Circulation, 110 (11), 1456-62
PubMed 15326072

Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B (2004)
Prognostic significance of left ventricular mass change during treatment of hypertension
JAMA, 292 (19), 2350-6
PubMed 15547162

Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE (2004)
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy
J Hum Hypertens, 18 (6), 375-80
PubMed 15057253

Gerdts E, Roman MJ, Palmieri V, Wachtell K, Smith G, Nieminen MS, Dahlöf B, Devereux RB (2004)
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
J Hum Hypertens, 18 (6), 417-22
PubMed 15103312

Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B (2004)
N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis
Eur J Heart Fail, 6 (3), 313-7
PubMed 14987582

Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B (2004)
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study
Kidney Int Suppl (92), S56-8
PubMed 15485419

Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y, LIFE substudy (2004)
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
J Hypertens, 22 (9), 1805-11
PubMed 15311110

Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB (2004)
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study
Hypertension, 45 (1), 46-52
PubMed 15583076

Kontos J, Papademetriou V, Wachtell K, Palmieri V, Liu JE, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB (2004)
Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study
J Hum Hypertens, 18 (6), 431-6
PubMed 15042117

Li ZB, Wachtell K, Okin PM, Gerdts E, Liu JE, Nieminen MS, Jern S, Dahlöf B, Devereux RB (2004)
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study
J Hum Hypertens, 18 (6), 397-402
PubMed 15071485

Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahlöf B (2004)
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study
J Hum Hypertens, 18 (6), 403-9
PubMed 15057252

Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, Papademetriou V, Nieminen MS, Rokkedal J, Dahlöf B, Devereux RB (2004)
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)
Am J Cardiol, 94 (8), 1076-80
PubMed 15476632

Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB (2004)
Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy
J Hum Hypertens, 18 (6), 453-9
PubMed 15085167

Olsen MH, Wachtell K, de Simone G, Palmieri V, Dige-Petersen H, Devereux RB, Ibsen H, Rokkedal J (2004)
Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy
J Hum Hypertens, 18 (6), 437-43
PubMed 15014540

Olsen MH, Wachtell K, Meyer C, Hove JD, Palmieri V, Dige-Petersen H, Rokkedal J, Hesse B, Ibsen H (2004)
Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy
J Hum Hypertens, 18 (6), 445-52
PubMed 15014539

Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P (2004)
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study
J Hypertens, 22 (8), 1597-604
PubMed 15257184

Palmieri V, Wachtell K, Bella JN, Gerdts E, Papademetriou V, Nieminen MS, Dahlöf B, Roman MJ, Devereux RB (2004)
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study
J Hum Hypertens, 18 (6), 423-30
PubMed 15002006

Wachtell K, Papademetriou V, Smith G, Gerdts E, Dahlöf B, Engblom E, Aurigemma GP, Bella JN, Ibsen H, Rokkedal J, Devereux RB (2004)
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
Am Heart J, 148 (3), 538-44
PubMed 15389245

Wiinberg N, Bang LE, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Rokkedal J, Ibsen H, Devereux RB (2004)
24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy
J Hum Hypertens, 18 (6), 391-6
PubMed 15057254

Publications 2003

Abildstrom SZ, Jensen BT, Agner E, Torp-Pedersen C, Nyvad O, Wachtell K, Ottesen MM, Kanters JK, BEAT Study Group (2003)
Heart rate versus heart rate variability in risk prediction after myocardial infarction
J Cardiovasc Electrophysiol, 14 (2), 168-73
PubMed 12693499

Aurigemma GP, Devereux RB, Wachtell K, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B (2003)
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment
Am J Hypertens, 16 (3), 180-6
PubMed 12620695

Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, Wachtell K, LIFE study group (2003)
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
Lancet, 362 (9384), 619-20
PubMed 12944063

Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators (2003)
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study
Am Heart J, 145 (5), 919-25
PubMed 12766755

Olsen MH, Hjerkinn E, Wachtell K, Høieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Julius S, Ibsen H (2003)
Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy
J Hum Hypertens, 17 (5), 305-11
PubMed 12756402

Palmieri V, Bella JN, Roman MJ, Gerdts E, Papademetriou V, Wachtell K, Nieminen MS, Dahlöf B, Devereux RB (2003)
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study
J Hypertens, 21 (4), 781-7
PubMed 12658025

Palmieri V, Okin PM, Bella JN, Gerdts E, Wachtell K, Gardin J, Papademetriou V, Nieminen MS, Dahlöf B, Devereux RB, Losartan Intervention For End-point reduction in hypertension (2003)
Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study
Hypertension, 41 (1), 75-82
PubMed 12511533

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P (2003)
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
Ann Intern Med, 139 (11), 901-6
PubMed 14644892

Publications 2002

Bella JN, Wachtell K, Boman K, Palmieri V, Papademetriou V, Gerdts E, Aalto T, Olsen MH, Olofsson M, Dahlöf B, Roman MJ, Devereux RB (2002)
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)
Am J Cardiol, 89 (3), 337-41
PubMed 11809439

Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B (2002)
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study
J Hypertens, 20 (7), 1445-50
PubMed 12131543

Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, Dahlöf B, Devereux RB, Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (2002)
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
Hypertension, 39 (3), 739-43
PubMed 11897755

Gerdts E, Papademetriou V, Palmieri V, Boman K, Björnstad H, Wachtell K, Giles TD, Dahlöf B, Devereux RB, Losartan Intervention For End (LIFE) point reduction in hypertension study (2002)
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
Am J Cardiol, 89 (4), 399-402
PubMed 11835919

Herlitz J, Wikstrand J, Denny M, Fenster P, Heywood T, Masszi G, Rasmussen S, Thorgeirsson G, Wachtell K, MERIT--HF Study Group (2002)
Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension
J Card Fail, 8 (1), 8-14
PubMed 11862577

Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, LIFE study group (2002)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 20 (9), 1879-86
PubMed 12195132

Olsen MH, Wachtell K, Borch-Johnsen K, Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB, Ibsen H (2002)
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction
J Hum Hypertens, 16 (8), 591-5
PubMed 12149666

Olsen MH, Wachtell K, Hermann KL, Bella JN, Dige-Petersen H, Rokkedal J, Ibsen H (2002)
Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy
Blood Press, 11 (5), 285-92
PubMed 12458651

Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H (2002)
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
Am Heart J, 144 (3), 530-7
PubMed 12228792

Olsen MH, Wachtell K, Aalkjaer C, Dige-Petersen H, Rokkedal J, Ibsen H (2002)
Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
Am J Hypertens, 15 (5), 398-404
PubMed 12022241

Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, Aalto T, Gerdts E, Devereux RB (2002)
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
Circulation, 105 (9), 1071-6
PubMed 11877357

Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB (2002)
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
Am Heart J, 144 (6), 1057-64
PubMed 12486431

Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H (2002)
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study
J Hypertens, 20 (3), 405-12
PubMed 11875307

Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Wright JT, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB (2002)
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction
Am Heart J, 143 (2), 319-26
PubMed 11835038

Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB (2002)
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study
Circulation, 106 (2), 227-32
PubMed 12105163

Publications 2001

Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlöf B, Roman MJ, Devereux RB (2001)
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study
J Hypertens, 19 (1), 127-34
PubMed 11204292

Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B (2001)
Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study
Blood Press, 10 (2), 74-82
PubMed 11467763

Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM (2001)
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction
J Hypertens, 19 (10), 1883-91
PubMed 11593111

Olsen MH, Wachtell K, Hermann KL, Bella JN, Andersen UB, Dige-Petersen H, Rokkedal J, Ibsen H (2001)
Maximal exercise capacity is related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
Am J Hypertens, 14 (12), 1205-10
PubMed 11775128

Olsen MH, Wachtell K, Aalkjaer C, Devereux RB, Dige-Petersen H, Ibsen H (2001)
Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension
Am J Hypertens, 14 (9 Pt 1), 861-7
PubMed 11587150

Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, Nieminen MS, Dahlöf B, de Simone G, Devereux RB (2001)
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study
Am Heart J, 141 (5), 784-91
PubMed 11320367

Papademetriou V, Devereux RB, Narayan P, Wachtell K, Bella JN, Gerdts E, Chrysant SG, Dahlöf B (2001)
Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study
Am J Hypertens, 14 (8 Pt 1), 768-74
PubMed 11497192

Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlöf B, Smith G, Roman MJ, Ibsen H, Aurigemma GP, Devereux RB (2001)
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint
Am J Cardiol, 87 (1), 54-60
PubMed 11137834

Publications 2000

Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Dahlöf B (2000)
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension
J Hypertens, 18 (8), 1129-38
PubMed 10954006

Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H (2000)
A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
Blood Press, 9 (2-3), 132-9
PubMed 10855737

Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S (2000)
Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia
J Hypertens, 18 (1), 75-81
PubMed 10678546

Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, Roman MJ, Papademetriou V, Ibsen H, Rokkedal J, Devereux RB (2000)
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study
Hypertension, 35 (1 Pt 1), 6-12
PubMed 10642267

Wachtell K, Smith G, Gerdts E, Dahlöf B, Nieminen MS, Papademetriou V, Bella JN, Ibsen H, Rokkedal J, Devereux RB (2000)
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint
Am J Cardiol, 85 (4), 466-72
PubMed 10728952

Publications 1999

Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH (1999)
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group
Am Heart J, 137 (6), 1062-9
PubMed 10347332

Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H (1999)
Influence of non-steady state during isoglycemic hyperinsulinemic clamp in hypertension. A LIFE substudy
Blood Press, 8 (4), 207-13
PubMed 10697300

Publications 1997

Wachtell K, Ibsen H, Olsen MH, Laybourn C, Christoffersen JK, Nørgaard HH, Mantoni MY, Lund JO (1997)
[Occurrence of renal artery stenosis in patients with peripheral arteriosclerosis and hypertension]
Ugeskr Laeger, 159 (46), 6822-4
PubMed 9411995

Publications 1996

Wachtell K, Ibsen H, Olsen MH, Laybourn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO (1996)
Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension
J Hum Hypertens, 10 (2), 83-5
PubMed 8867560

Wachtell K, Molzen AH, Hansen FM (1996)
[Nephrocalcinosis and urolithiasis as primary symptoms in Boeck's sarcoidosis]
Ugeskr Laeger, 158 (12), 1685-6
PubMed 8644414